/L), comprising 1% myeloblasts and 60% mature lymphocytes, macrocytic anemia (Hb, 92 g/L; mean corpuscular volume, 104.0 fL), and thrombocytopenia (platelets [PLT] , 31 × 10 9 /L). Bone marrow (BM) examination indicated a normocellular marrow for his age (cellularity, 20%), including 21.6% myeloblasts and 16.6% mature lymphocytes (Fig. 1) . The clot section showed multiple irregularly shaped medium-to-large lymphoid nodules, comprising small mature lymphocytes. Immunohistochemicalstains of the BM clot section showed that the myeloblasts were positive for CD34 and CD117, and the small lymphoid cells in the lymphoid nodules were positive for CD5, CD19, and CD23.
Flow cytometric immunophenotyping of BM aspirate showed two populations: one positive for myeloblast markers (CD34, CD13, CD33, CD117, and HLA-DR) and another for B lymphoid markers (CD5, CD19, CD20, and CD23) along with co-expression of CD19 and CD5 ( Fig. 2A) . Chromosome analysis showed an abnormal karyotype (46,XY,del(13)(q14),add(14)(q32) [3] On the basis of the WHO 2008 criteria, the patient was diagnosed as having AML, NOS (AML with maturation). However, he did not receive induction chemotherapy for AML because of his advanced age and comorbidities such as hypertension and worsening left thigh cellulitis. He was treated with a hypomethyl- /L with 12% segmented neutrophils, 84% mature lymphocytes, and 4% monocytes). BM aspirates showed 6% myeloblasts and 24% mature lymphocytes. The AML appeared to respond to chemotherapy. He was treated with empirical antibiotic therapy for suspected pneumonia. After being discharged, he has been undergoing routine follow-up, without a third cycle of decitabine treatment.
We describe a case of simultaneous development of AML and CLL. Regarding primary etiology, impaired immunity and old age have been discussed previously [6] ; our patient had both these risk factors. Graf [7] suggested that, due to the plasticity of neoplastic common progenitor cells, the neoplastic transformation of common progenitor cells could occur during hematopoietic differentiation, and they could develop into two separate lineages (myeloid and lymphoid). Although we detected two populations of myeloid and lymphoid lineages withflow cytometry, both chromosomal abnormalities, add(14q) and del(13), were observed in the same clones on karyotyping. Del(13q) could be found in myeloid and lymphoid malignancies. While del(14q) and 14q32-related translocation are associated with B lineage malignancies, the significance of additional material on 14q32 such as add(14q) in tumor cytogenetics is unclear. Moreover, 14q32/IGH rearrange- ment of B-lymphoid malignancies was not detected, suggesting that both myeloid and lymphoid cells originated from the same clone. Hou et al [8] reported a human B-cell/myeloid common progenitor, which matured into a lineage according to the culture environment; thus, the pathways for myeloid and lymphoid development may not be very strict. In the current case, we believe that a common progenitor clone expanded and differentiated into two separate lineages. The flow cytometric sorting of the two populations into myeloid or lymphoid cells, followed by karyotyping of each population, is required to confirm the clonality. Thus, we report a case of concomitant occurrence of AML and CLL. On the basis of the chromosomal abnormalities in this patient, we suspect that the myeloid and lymphoid lineages were evolved from common progenitor cells.
